

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
Cover	Cover page			Updated cover information.
9	Preface	Summary of Changes	Listing of major changes updated	Revised the section with the list of major changes including additions, deletions, and modifications made to the 2027 manual and appendices. See manual.
10	Preface	2027 Updates	Listing of additional 2027 changes updated	Revised the list cancer coding and staging changes for 2027.
12	Preface	SEER Site-Specific Factors 1 – 6	Section updated	Added sentence (as SEER Site-Specific Factor 1 (HPV) is moving to the SSDI Manual): See the SSDI Manual, Appendix A for <i>SEER Site-Specific Factor 1</i> coding instructions.
14	Reportability	Reportable Diagnosis List	Introduction revised	Revised second introductory paragraph to include the new Appendix E.3: Refer to Appendix E.1 and Appendix E.3 for reportable examples and to the ICD-O-3.2 Updates for new/changed behaviors and terms.
14	Reportability	Reportable Diagnosis List	Item 1.a revised	Added 1.a.i and ii: i. All gastrointestinal stromal tumors (GIST) are reportable as behavior /3 including GIST described with terms such as benign, borderline, indolent, low risk score, NOS, or behavior unknown as of 01/01/2021 ii. Thymomas are reportable as a behavior /3 unless stated to be benign as of 01/01/2021 Revised 1.a.viii, 2nd bullet, Intraepithelial neoplasia (IEN), high grade, grade II, grade III Moved multiple reportable neoplasia-related terms to a newly created Appendix E.3 that incorporates histology terms from 1.a.viii, Appendix E.1, Appendix E.2, and other sources for IEN, dysplasia, and hyperplasia. Added: For a list of IEN, dysplasia, and hyperplasia examples, refer to Appendix E.3.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
15	Reportability	Reportable Diagnosis List	Item 1.b revised	Moved non-reportable neoplasia-related terms and a newly created Appendix E.3 that incorporates histology terms from 1.a.viii, Appendix E.1, and Appendix E.2 for IEN, dysplasia, and hyperplasia. Added 1.b.iv: Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (8349/1) (C739) as of 01/01/2021 Added: Refer to Appendix E.2 and Appendix E.3 for non-reportable examples.
16-17	Reportability	Reportable Examples; Non-Reportable Examples	Text updated	Reportable Examples: Refer to Appendix E.1 and Appendix E.3 for reportable examples. Non-Reportable Examples: Refer to Appendix E.2 and Appendix E.3 for non-reportable examples.
17	Reportability	Documentation of Reportable Diagnoses	Medical practitioner replaced	A reportable diagnosis made by a recognized physician or/or advanced practice provider (PAPP) may appear on a variety of medical documentation including but not limited to (see list). For purposes of this manual, the terms “physician” and “PAPP” are used interchangeably. Both terms refer to a physician and/or advanced practice provider. PAPP includes physician, physician assistant, nurse practitioner, and nurse midwife.
17	Reportability	Documentation of Reportable Diagnoses	Section added	Added section under Documentation of Reportable Diagnoses: Determining reportability using imaging reports. See manual.
22	Reportability	Instructions for Reporting Pediatric Cancers	Section added	Added a section regarding the reporting of pediatric cancer cases. See manual.
24	Changing Information on the Abstract		Dates in example revised	Updated the dates in the example under #4.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
25	Determining Multiple Primaries		Topography codes revised	Updated topography codes for Head and Neck to match the Solid Tumor Manual.
31	Section I: Basic Record Identification	NAACCR Record Version	Code and description added	Added code 270 and description, 2027 Version 27.
36	Section II: Information Source	Class of Case	Data item added	See manual. If registry was abstracting prior to 2027: Codes 11 and 12 were removed in 2027.
63	Section III: Demographic Information	Geocode Address at Diagnosis-- Number and Street	Data item added	See manual.
64	Section III: Demographic Information	Geocode Address at Diagnosis— City	Data item added	See manual.
65	Section III: Demographic Information	Geocode Address at Diagnosis— State	Data item added	See manual.
66	Section III: Demographic Information	Geocode Address at Diagnosis-- Postal Code	Data item added	See manual.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
90	Section III: Demographic Information	Race 1, 2, 3, 4, 5	Coding instructions 10 and 11 updated	Updated Coding Instructions 10 and 11: 10. Use the appropriate non-specific code 96 (Other Asian including Asian, NOS), 97 (Pacific Islander, NOS), or 98 (Some other race) when there is no race code for a specific race documented in the patient record 11. Do not use code 98 (Some other race) a. Alone for “multi-racial.” If multi-racial is the only information available, assign code 99. See Coding Examples below. b. When race is unknown (code 99)
93	Section III: Demographic Information	IHS Link	Note updated	Information from IHS linkage can be used to update race from unknown to code 03. Follow the priority rules for recording race.
95	Section III: Demographic Information	Spanish Surname or Origin	Coding Example 4 revised	Example 4: Patient has two last names, one of the last names is on the Spanish surname list. Code as 7 (Spanish surname only) using coding instruction 5.
105	Section IV: Description of this Neoplasm	Date of Diagnosis	Introductory paragraph revised	The date of diagnosis is the month, day, and year the reportable neoplasm was first identified, clinically or microscopically, by a physician and/or advanced practice provider (PAPP). PAPP includes physician, physician assistant, nurse practitioner, and nurse midwife.
107	Section IV: Description of this Neoplasm	Date of Diagnosis	Coding Instruction 1 revised	Code the month, day, and year the tumor was first diagnosed, clinically or microscopically, by a recognized PAPP.
107	Section IV: Description of this Neoplasm	Date of Diagnosis	Coding Instruction 3 example deleted	Revised Coding Instruction 3: Deleted Example 2 and corresponding note.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
107-109	Section IV: Description of this Neoplasm	Date of Diagnosis	Coding Instructions examples--dates revised	Updated dates in the examples used in several Coding Instructions.
108	Section IV: Description of this Neoplasm	Date of Diagnosis	Coding Instruction 6.a edited	Revised Coding Instruction 6.a: A recognized PAPP says that, in retrospect , the patient had cancer at an earlier date
109	Section IV: Description of this Neoplasm	Date of Diagnosis	Cases Diagnosed Before Birth examples--dates revised	Updated dates in the example.
122	Section IV: Description of this Neoplasm	Laterality	Note deleted	Deleted the note in the section Sites for Which Laterality Codes Must Be Recorded: Laterality will be automatically coded to 0 in SEER*DMS for sites not listed in the table below.
124	Section IV: Description of this Neoplasm	Diagnostic Confirmation	Introductory paragraph revised	Revised second sentence, first paragraph: The best method could occur at any time during the patient's first course of treatment.
124	Section IV: Description of this Neoplasm	Diagnostic Confirmation	Coding Instruction for Solid Tumors 2 revised	Revised Coding Instruction 2: Change to a higher-priority code, if at ANY TIME during the first course of treatment the patient has a diagnostic confirmation with a higher priority.
126	Section IV: Description of this Neoplasm	Diagnostic Confirmation	Heme codes removed	Revised the section header to: Codes and Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9590/3-9993/3). Deleted the tables of codes for Hematopoietic and Lymphoid Neoplasms Deleted the section header: Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9590/3-9993/3)

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
127	Section IV: Description of this Neoplasm	Histologic Type ICD-O-3	Dates in ICD-O- 3.2 Update updated	The 2027 ICD-O-3.2 Update Guidelines provides the changes to ICD-O-3.2 including new terminology and reportability changes effective for cases diagnosed 01/01/2027 forward.
127	Section IV: Description of this Neoplasm	Histologic Type ICD-O-3	Histology Coding for Solid Tumors table updated	Revised text and tables to refer to site groups: Site-specific histology coding rules cover the following sites groups: Updated Topography in Head and Neck and Lung site groups: Head and Neck: C000-C148, C300-C339, C410, C411, C479, C754, C755 Lung: C340-C343, C348, C349
130	Section IV: Description of this Neoplasm	Behavior Code	In Situ and Invasive section- exception added	Exception: For an ovarian mucinous borderline tumor with microinvasion, the term "microinvasion" is not an indication of malignancy. Low malignant potential/borderline ovarian tumors are defined by the pathology of the primary tumor and are not affected by microinvasion or invasion in implants. Though a case may be staged, this does not mean it is reportable.
132- 133	Section IV: Description of this Neoplasm	Cancer PathCHART Site - Morphology Combination Standards	Section revised	Updated information in this section. See manual.
144	Section IV: Description of this Neoplasm	Tumor Size Summary	Schema IDs updated	Added schema to Table. Schemas for which Tumor Size Affects Staging: Minor Salivary Gland V9 09082
148	Section V: Stage of Disease at Diagnosis	Extent of Disease Primary Tumor	Text of codes updated	Edited Codes section to move text to table row for Code Description.
149	Section V: Stage of Disease at Diagnosis	Extent of Disease Regional Nodes	Codes table updated	Edited Codes section to move text to table row for Code Description.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
150	Section V: Stage of Disease at Diagnosis	Extent of Disease Mets	Codes table updated	Edited Codes section to move text to table row for Code Description. Added table row for Code 70, Distant metastasis, NOS.
152	Section V: Stage of Disease at Diagnosis	Summary Stage 2018	Code Description revised	Revised Code 4, Code Description: Regional by BOTH direct extension AND lymph node involvement.
158	Section VI: Stage-related Data Items	Lymphovascular Invasion	Coding Instruction 10.f added	Added Coding Instruction 10.f: f. For thyroid, thyroid medullary, or adrenal gland: The pathology report states LVI is present but does not provide the required further specification lymphatic invasion, angioinvasion, or both lymphatic and angioinvasion. It is recommended that this be clarified with the physician as this distinction is required for CAP protocol.
	Section VI: Stage-related Data Items	Macroscopic Evaluation of the Mesorectum	Data item deleted	Data item moved to the site-specific data item (SSDI) manual.
	Section VI: Stage-related Data Items	SEER Site- specific Factor 1	Data item deleted	Data item moved to the site-specific data item (SSDI) manual.
171	Section VI: Stage-related Data Items	Additional Stage-related Data Items/SSDIs	Section updated and tables removed	Revised introductory paragraphs. Removed tables. See manual.
175	Section VII: First Course of Therapy	Treatment Timing	Coding Instruction 5 revised	Code the treatment on each abstract when a patient has multiple primaries and the treatment given for one primary also is clinically recognized to affect/treat the other primary.
178	Section VII: First Course of Therapy	Date Therapy Initiated	Coding Instruction 3 note added	Note: Code date therapy initiated as the date the stereotactic core biopsy was performed when the entire tumor was removed.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
179	Section VII: First Course of Therapy	Date Therapy Initiated	Coding Instruction 4 example dates updated	Updated the dates in the example under Coding Instruction 4.
184	Section VII: First Course of Therapy	Surgery of Primary Site 2023	Coding Instruction 1 note revised	Note: Codes A000 and B000 exclude all sites and histologies that are coded A980. (See Coding Instruction 12 below.)
188	Section VII: First Course of Therapy	Surgical Margins of the Primary Site	Coding Instruction 1.a added	Added Coding Instruction 1.a: 1. Assign code 0 when a. There is documentation of no residual disease on the pathology report
189	Section VII: First Course of Therapy	Surgical Margins of the Primary Site	Coding Instruction 7.c updated and 7.d and 7.e added	c. When patient has a transurethral biopsy of bladder tumor (TURBT) and surgical margins are not mentioned in the TURBT pathology report. The operative report may mention no residual tumor. d. When the physician documents the absence of residual invasive carcinoma or confirms that no residual cancer/carcinoma is present e. When surgical margin status is not documented
195	Section VII: First Course of Therapy	Date of Sentinel Lymph Node Biopsy	Introductory paragraph revised	<i>Date of Sentinel Lymph Node Biopsy</i> , effective 01/01/2018, records the date of the sentinel lymph node biopsy procedure. SEER requires this data item for breast and cutaneous melanoma cases only.
194	Section VII: First Course of Therapy	Date of Sentinel Lymph Node Biopsy	Coding Instruction 6.c added	Revised Coding Instruction 6 layout (6.a and b); added 6.c: 6. Leave this date blank a. When sentinel lymph node biopsy was attempted, but unsuccessful (e.g., failed to map) b. For cases other than breast and cutaneous melanoma c. When Sentinel Lymph Nodes Examined [NAACCR Item #834] is assigned code 00, 95, or 99

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
195	Section VII: First Course of Therapy	Sentinel Lymph Nodes Examined	Introductory paragraphs revised	<i>Sentinel Lymph Nodes Examined</i> , effective 01/01/2018, records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. SEER requires this data item for breast and cutaneous melanoma cases only. This data item may be left blank for cases other than breast and cutaneous melanoma. If collected for other sites, refer to the STORE Manual for coding instructions.
195	Section VII: First Course of Therapy	Sentinel Lymph Nodes Examined	Code Description revised	Revised Code 99: It is unknown whether sentinel nodes were examined; not stated in patient record; not applicable
196	Section VII: First Course of Therapy	Sentinel Lymph Nodes Positive	Introductory paragraphs revised	<i>Sentinel Lymph Nodes Positive</i> , effective 01/01/2018, the exact number of sentinel lymph nodes found to contain metastases. SEER requires this data item for breast and cutaneous melanoma cases only. This data item may be left blank for cases other than breast and cutaneous melanoma. If collected for other sites, refer to the STORE Manual for coding instructions.
196	Section VII: First Course of Therapy	Sentinel Lymph Nodes Positive	Coding Instruction 4.a and 4.b revised	4. FOR BREAST ONLY a. Record the number of positive SLNs if the number is provided on pathology report. If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, record the total number of positive sentinel nodes identified in this data item, and record the total number of positive regional lymph nodes identified (both sentinel and regional) in <i>Regional Nodes Positive</i> [NAACCR Item #820]. b. Use code 97 when a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, but the number of sentinel nodes is unknown/not stated on the pathology report. Record the total number of positive regional lymph nodes biopsied/dissected (which includes the sentinel lymph nodes) in <i>Regional Nodes Positive</i> (NAACCR Item #820).
202	Section VII: First Course of Therapy	Regional Nodes Examined	Code Description revised	Revised Code 99: It is unknown whether nodes were examined; not stated in patient record; not applicable or negative

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
225	Section VII: First Course of Therapy	Chemotherapy	Definition added for Coding Tumor Embolization	Added: Bland embolization: There is no embolizing agent and/or the agent is not chemotherapeutic or radiation.
227	Section VII: First Course of Therapy	Hormone Therapy	Coding Instruction 3 revised	Revised Coding Instruction 3: Code as treatment for both primaries when the patient receives hormone therapy for one primary and the hormone therapy is clinically recognized to also affect the other primary.
228	Section VII: First Course of Therapy	Hormone Therapy	Coding Example 2 revised	Revised Coding Example 2: Example 2: Follicular, papillary, and oncocytic cancers of the thyroid are often treated with thyroid hormone to suppress serum thyroid-stimulating hormone (TSH). If a patient with papillary and/or follicular cancer of the thyroid is given a thyroid hormone, code the treatment in this data item.
232	Section VII: First Course of Therapy	Immunotherapy	Dates in example updated	Updated dates in the example following the note under Important update effective for diagnosis date January 1, 2013, forward. See manual.
232	Section VII: First Course of Therapy	Immunotherapy	Text deleted	Deleted tositumomab (Bexxar) from the sentence regarding conjugated monoclonal antibodies.
233	Section VII: First Course of Therapy	Immunotherapy	Coding Instruction 2 added	Added Coding Instruction 2: Code as treatment for both primaries when the patient receives immunotherapy for one primary and it is clinically recognized to also affect the other primary.
234	Section VII: First Course of Therapy	Hematologic Transplant and Endocrine Procedures	Code Description modified	Revised Code 86: Transplant procedure and/or endocrine therapy was not administered; it was recommended by the patient's physician but was not administered as part of first course therapy. No reason was noted in the patient record.
	Section VII: First Course of Therapy	Neoadjuvant Therapy data items	Data items deleted	The neoadjuvant data items were removed from the SEER manual and have been moved to the SSDI Manual: Neoadjuvant Therapy Neoadjuvant Therapy--Clinical Response Neoadjuvant Therapy--Treatment Effect

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
239	Section VII: First Course of Therapy	Date Other Treatment Started	Introductory paragraph revised	Revised introductory paragraph, second sentence: Examples include phlebotomy or aspirin (for essential thrombocytopenia cases only) when administered as forms of treatment.
240	Section VII: First Course of Therapy	Other Therapy	Coding Instruction 2.a revised	Revised first sentence in Coding Instruction 2.a: Hematopoietic treatments such as phlebotomy or aspirin (when used for essential thrombocytopenia cases only).
241	Section VII: First Course of Therapy	Other Therapy	Coding Instruction 2.e added	Added Coding Instruction 2.e: Bland embolization: No embolizing agent is provided and/or the agent is not chemotherapeutic or radiation, including terms such as “tumor embolization” or “embolization of the tumor” for sites other than the liver.
241	Section VII: First Course of Therapy	Other Therapy	Coding Instruction 3 note added	Added note to Coding Instruction 3: Note 2: Assign code 2 for any non-FDA approved cancer treatment.
241	Section VII: First Course of Therapy	Other Therapy	Coding Instruction 4 revised and note added	Revised Coding Instruction 4: Assign code 3 when the patient is enrolled in a double blind clinical trial. When the trial is complete and the types of treatment are revealed, i.e., code is broken, review and code the FDA approved treatment actually administered. Note: If the code is broken, and the investigational drug has not been FDA approved, assign code 2.
242	Section VII: First Course of Therapy	Other Therapy	Definition added for Coding Tumor Embolization	Bland embolization: There is no embolizing agent and/or the agent is not chemotherapeutic or radiation.
248	Section VIII: Follow Up	Cancer Status Following First Course of Treatment	Data item added	See manual.
250	Section VIII: Follow Up	Date of Cancer Status Following First Course of Treatment	Data item added	See manual.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
253	Section VIII: Follow Up	Disease Follow-up or First Recurrence/Progression	Data item revised	This existing data item including codes and coding instructions has been updated for 2027. It was previously titled Recurrence Type--1 st . See manual.
255	Section VIII: Follow Up	Disease Follow-up or First Recurrence/Progression Date	Data item revised	This existing data item including codes and coding instructions has been updated for 2027. It was previously titled Recurrence Date--1 st . See manual.
280	Section IX: Administrative Codes	Over-ride Flag for Sex Assigned at Birth	Data item added	See manual.
	Appendix A	County Codes	References information updated	Updated references and dates references accessed.
	Appendix B	Country and State Codes	References dates and information updated	Updated dates references were accessed. Revised country name to Bahamas (The); formerly Bahamas (the)
	Appendix C: Site Specific Coding Modules	Coding Guidelines-Colon	Instruction added	Added: Code C189 when the only information provided for primary site is "colorectal."
	Appendix C: Site Specific Coding Modules	Coding Guidelines-Esophagus	Instruction added	Added: Code RFA when used to treat high-grade dysplasia of the esophagus when part of the planned first course of therapy.
	Appendix C: Site Specific Coding Modules	Coding Guidelines-Thyroid	Coding instructions updated	Revised Coding Hormone Therapy section and added note. See guidelines.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
	Appendix C: Site Specific Coding Modules	Coding Guidelines-Tongue	Primary site revisions made	Added list of topography sites and codes. Updated right oral tongue to C023.
	Appendix C: Site Specific Coding Modules	Neoadjuvant Therapy--Treatment Effect, all	Appendix C Neoadjuvant Therapy--Treatment Effect files removed	Removed all site-specific documents from Appendix C; incorporated into SSDI Manual.
	Appendix C: Site Specific Coding Modules	Surgery Codes-Brain	SEER Note revised	Edited SEER Note for code A200: [SEER Note: Do not assign code A200 for stereotactic biopsy of brain tumor. This does not qualify as a surgical procedure. SEER no longer records this information under Surgery of Primary Site.]
	Appendix C: Site Specific Coding Modules	Surgery Codes-Brain	SEER Note added	Added SEER Note: A550 Gross total resection of lobe of brain (lobectomy) [SEER Note: Brain lobectomies are rarely performed for the treatment of brain tumors. In most cases, only the tumor is removed (codes A300 and below), rather than an entire lobe of the brain. Before assigning codes A400 or A550, confirm that a lobe of the brain—not just the tumor tissue—was removed.]
	Appendix C: Site Specific Coding Modules	Surgery Codes-Ovary	SEER Note revised	Revised SEER Note to remove (salpingo): A280 WITH hysterectomy [SEER Note: Also use code A280 for current unilateral oophorectomy with previous history of hysterectomy.]
	Appendix D	Race and Nationality Descriptions	References and list updated	Updated list of references and links.
	Appendix E	E.1 Reportable Examples	Reportable examples revised	Revised RADS histology terms. Moved select histology terms to Appendix E.3. See manual.

SEER Program Coding and Staging Manual 2027 - Summary of Changes

This table lists the changes in the 2027 manual by page number.

Page	Section	Data Item	Change	Notes/Comments
	Appendix E	E.1 Reportable Examples	Reportable examples added	Thyroid Category VI Gastrointestinal stromal tumor (GIST) Thymoma Cerebral cavernous malformation
	Appendix E	E.2 Non-Reportable Examples	Non-reportable examples revised	Select histology terms moved to Appendix E.3. See manual. Removed cavernous malformation.
	Appendix E	E.3	Appendix E.3 added	Created Appendix E.3 for: Examples of Reportable and Non-reportable Intraepithelial Neoplasia, Dysplasia, and Hyperplasia Terms